Published in final edited form as:

Curr Colorectal Cancer Rep. 2017 April ; 13(2): 111–118. doi:10.1007/s11888-017-0362-9.

Gut Microbiome and Colon Cancer: Role of Bacterial Metabolites and Their Molecular Targets in the Host

Yangzom D. Bhutia, Ph.D.,

Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA, Tel.: 806-743-1282

Jiro Ogura, Ph.D.,

Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA, Tel.: 806-743-4101

Sathish Sivaprakasam, Ph.D., and

Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA, Tel.: 806-743-4117

Vadivel Ganapathy, Ph.D.

Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA

Abstract

Purpose of review—The relationship between colonic bacteria and the host is symbiotic, but how communication between the two partners occurs is just beginning to be understood at the molecular level. Here, we highlight specific products of bacterial metabolism that are present in the colonic lumen and their molecular targets in the host that facilitate this communication.

Recent findings—Colonic epithelial cells and mucosal immune cells express several cell-surface receptors and nuclear receptors that are activated by specific bacterial metabolites, which impact multiple signaling pathways and expression of many genes. In addition, some bacterial metabolites also possess the ability to cause epigenetic changes in these cells via inhibition of selective enzymes involved in the maintenance of histone acetylation and DNA methylation patterns.

Summary—Colonic bacteria communicate with their host with selective metabolites that interact with host molecular targets. This chemical communication underlies a broad range of the biology and function of colonic epithelial cells and mucosal immune cells, which protect against inflammation and carcinogenesis in the colon under normal physiological conditions.

Corresponding author: Vadivel Ganapathy, Ph. D., Tel.: 806-743-2518, vadivel.ganapathy@ttuhsc.edu.

Conflict of Interest

Yangzom D. Bhutia, Jiro Ogura, Sathish Sivaprakasam, and Vadivel Ganapathy declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent All reported studies/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards, including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines. The data reported as “unpublished” were from animal studies performed with approval from the Institutional Animal Care and Use Committee.

Keywords

Bacteria-host symbiosis; Colonic inflammation; Colon cancer; Bacterial metabolites; Cell-surface receptors; Nuclear receptors; Epigenetics; Histone deacetylases; TET DNA demethylases; HIF1 α -prolylhydroxylases; NDRG3

Introduction

From the first day of life, we live in co-habitation with microorganisms in different parts of our bodies. Colonization of our bodies by these microorganisms begins at birth irrespective of the mode of delivery, even though the specific types of microorganisms that we encounter at birth may differ between vaginal and Cesarean section delivery. Until recently, it was thought that adult humans harbor approximately 10 times more bacterial cells than the human cells, primarily based on a four decade-old estimate [1]. However, a recent study indicates that the ratio of bacterial cells to human cells in our body is significantly less, closer to a ratio of 1:1 [2**], with most of these bacteria residing in our large intestine.

Although the relationship between colonic bacteria and the host is often described as commensal, the relationship is actually symbiotic, with active communication between the bacteria and the host and both benefitting from the co-habitation. The benefits that the bacteria derive from the host are obvious; we provide the space for bacteria to colonize and also food for them to survive and grow. The benefits that the host derives from co-habitation are just beginning to be understood. Normal bacteria in the colon protect against enteric infections, aid in the maturation of colonic function, modulate the gut mucosal immune system, supply certain vitamins, promote water and electrolyte absorption, influence the epigenetic profile of epithelial cells, and maintain energy homeostasis [3–6].

It would be incorrect to assume that co-habitation results in only beneficial outcomes for host health. Colonic bacteria also play critical, causal roles in the development of colonic diseases as well as in a variety of systemic diseases [7–10]. As such, the recognition of the importance of gut microbiota to our health has been one of the hallmarks of the last decade, underlined by the initiation of the Human Microbiome Project by the National Institutes of Health. The initial efforts of the Human Microbiome Project focused on sequencing and annotating individual microbial genomes, but the focus has recently shifted to understanding the molecular mechanisms underlying the effective communication between bacteria and host. Specifically, bacterial metabolites are released into the colonic lumen, which then function as messengers between the bacteria and the host. The purpose of the current review is to summarize recent discoveries related to these bacterial metabolites and their molecular targets in the host and to highlight the significance of this chemical communication to host health and disease.

Bacterial Metabolites as the Messengers in the Communication between Colonic Bacteria and the Host

Colonic bacteria release specific metabolites via multiple metabolic pathways into the colonic lumen. The normal turnover of bacteria also releases metabolic intermediates from

the dead cells into the colonic lumen. Metabolite production and release depends on various factors, including the composition of the host diet and the bacterial strains that colonize the colon. Most of these metabolites are likely to have only local effects on the host cells in the vicinity of the bacteria (e.g., colonic epithelial cells, mucosal immune cells, enteric neurons), but some of these metabolites may enter the systemic circulation and elicit biological effects on cell types distant from the bacteria [11*]. The impact of the colonic bacteria and their metabolites on distant organs could also be due to mucosal immune cells in the gut lamina propria, which are biologically and immunologically altered and then travel to distant sites [12, 13**]. The circulating bacterial metabolites and immune cells, which are trained and programmed in the intestinal tract, provide a mechanistic connection between gut microbiota and systemic diseases such as diabetes, obesity, metabolic syndrome, atherosclerosis, autism, autoimmunity, and cancer [14–19].

Identity of Bacterial Metabolites and their Molecular Targets Relevant to Bacteria-Host Interaction

Table 1 lists bacterial metabolites in the colonic lumen that have been shown to induce significant biological effects locally on the colonic epithelial cells and mucosal immune cells as well as distantly on other organs. Table 1 also identifies respective host molecular targets for these metabolites. We have placed these metabolites in four groups, primarily based on their structure and/or origin. Group 1 (short-chain carboxylates) consists of the monocarboxylates acetate, propionate, butyrate, and lactate, as well as the dicarboxylate succinate. These are generated in the colonic lumen principally by bacterial fermentation of dietary fiber, but some of these are also found in normal diet (e.g., lactate in yogurt). The molecular targets for these metabolites include cell-surface G-protein-coupled receptors (GPR41, GPR43, GPR109A, GPR81, and GPR91), intracellular enzymes (HDACs, TETs, and PHD2), and an intracellular signaling component (NDRG).

Group 2 consists of tryptophan metabolites (indole, indole-3-aldehyde, indole-3-acetic acid, and indole-3-propionic acid). These metabolites are generated by colonic bacteria via metabolism of tryptophan synthesized by bacteria or from dietary sources. Their molecular targets are selective nuclear receptors (AhR and PXR).

Group 3 represents lipid metabolites arising from endogenous lipids in bacteria and/or dietary lipids. This includes the organic cation trimethylamine (TMA), secondary bile acids deoxycholic acid and lithocholic acid, and modified polyunsaturated fatty acids. In host cells, these lipid metabolites signal through nuclear receptors (FXR, PXR, PPAR α and PPAR γ) as well as cell-surface receptors (GPR40 and TAAR5). Group 4 is primarily comprised of bacterial cell wall components (lipopolysaccharide, peptidoglycans, and polysaccharide A). These metabolites act through cell-surface receptors (TLR4) and intracellular receptors (TLR2, NOD1 and NOD2).

Short-chain Carboxylates: Short-chain Fatty Acids

Colonic bacteria produce high concentrations of short-chain carboxylates in the lumen, which include the short-chain fatty acids acetate, propionate, and butyrate, the glycolysis

product lactate, and the citric acid cycle intermediate succinate. Among these, the short-chain fatty acids have been most extensively investigated for their effects on the colon. Colonic bacteria ferment carbohydrates and generate acetate, propionate, and butyrate as their major end products. Dietary fiber constitutes the majority of these fermentable carbohydrates. The combined luminal concentrations of these three fermentation products are in the range of 50–100 mM, with an approximate ratio of 6:3:1 for acetate, propionate, and butyrate, respectively. The beneficial effects of these short-chain fatty acids on colonic health have been known for several decades, but a majority of investigations in the area focused on butyrate as an inhibitor of histone deacetylases (HDACs) [20, 21]. Recent studies show that propionate is also an inhibitor of HDACs [22, 23], that butyrate functions selectively as an agonist for the cell-surface G-protein-coupled receptor GPR109A (also known as hydroxycarboxylic acid receptor 2 or HCAR2) [24], and that all three short-chain fatty acids serve as agonists for two other cell-surface G-protein-coupled receptors, identified as GPR41 and GPR43 [25–27].

There are two transporters in the colonic epithelium, expressed in the lumen-facing apical membrane, that mediate the uptake of short-chain fatty acids from the lumen: the H⁺-coupled monocarboxylate transporter MCT1 (SLC16A1) and the Na⁺-coupled monocarboxylate transporter SMCT1 (SLC5A8) [28, 29]. It is logical to presume that any transport mechanism involved in the uptake of an HDAC inhibitor into cells would suppress carcinogenesis because HDACs are upregulated in many cancers and HDAC inhibitors are effective in cancer therapy. However, a tumor-suppressive function has been unequivocally demonstrated only for SMCT1, not for MCT1 [30, 31]. In fact, the tumor-suppressive role of SMCT1 in the colon was discovered first [32], followed by the discovery of the functional identity of the transporter as the protein responsible for the Na⁺-coupled high-affinity uptake of short-chain fatty acids (including butyrate and propionate) in colonic epithelial cells [33]. Despite the ability of SMCT1 to function as a tumor suppressor *in vitro*, mice lacking the transporter do not demonstrate a significantly increased risk for cancer [34]. The tumor-suppressive function of the transporter is linked to the fiber content in the diet; even though the knockout mice did not show any difference in cancer risk when fed a diet rich in fiber, the mice exhibited increased cancer risk when fed a diet low in fiber [35**]. This finding appears to be directly linked to the high affinity of SMCT1 for butyrate and propionate, which makes the contribution of the transporter to the total uptake of these HDAC inhibitors in colonic epithelial cells insignificant when these metabolites are present at high concentrations, as in the setting of a high fiber diet.

In addition to their ability to influence the epigenetic profile of colonic epithelial cells, propionate, butyrate, and acetate also impact epithelial cell function by activating three different cell-surface receptors: GPR109A, GPR43, and GPR41 [25–27]. GPR109A (also known as hydroxycarboxylic acid receptor 2 or niacin receptor 1), a selective receptor for butyrate, is expressed on the lumen-facing apical membrane of colonic epithelial cells; its expression, together with butyrate, increases along the intestinal tract from jejunum to colon [36]. Interestingly, colonic bacteria regulate the expression of *HCAR2* (the gene encoding GPR109A) in the colon [36]; gene expression is markedly reduced in germ-free mice and returns to normal when the colons of the germ-free mice are colonized with bacteria. Activation of GPR109A elicits anti-inflammatory and tumor-suppressive effects. Conversely,

Gpr109a-null mice are more prone to experimental colitis and colon cancer. This study also showed that the butyrate receptor is expressed on mucosal immune cells and that the receptor on these immune cells as well as the receptor on colonic epithelial cells contribute to the protection against inflammation and carcinogenesis in the colon [37**].

The participation of immune-cell GPR109A in the maintenance of colonic health raises a critical question: what is the agonist for this receptor on the immune cells in the lamina propria? It is unlikely that the bacteria-derived butyrate would cross the colonic epithelial cells to the serosal side at concentrations high enough to activate the receptor on immune cells. Taggart et al. have shown that the ketone body β -hydroxybutyrate is the physiological agonist for GPR109A expressed in non-colonic tissues [38]. It remains to be determined if activation of the immune-cell GPR109A by circulating β -hydroxybutyrate is responsible for the contributions of the receptor signaling to colonic health. Despite the current lack of information on the identity of the agonist for the immune-cell GPR109A in the lamina propria of the colon, strong evidence exists for a critical role for this receptor in mucosal immune function. A recent study showed that GPR109A expressed on immune cells might function to enhance oral tolerance and protect against food allergy [39**].

The roles of GPR41 and GPR43, which are activated by all three short-chain fatty acids, remain unclear [40]. GPR41 is expressed in colonic epithelial cells as well as in enteroendocrine cells, [41] whereas GPR43 is expressed in colonic epithelial cells, enteroendocrine cells, and immune cells [42, 43]. However, based on published literature, it is difficult to determine whether the signaling pathways associated with these two receptors are anti-inflammatory or pro-inflammatory. For example, Trompette et al. [44] reported that *Gpr41*-null mice display increased inflammation, whereas Kim et al [45] showed that *Gpr41*-null mice have reduced inflammation. The same is true with GPR43, with some studies showing evidence of anti-inflammatory function of the receptor [46–50] and other studies showing the opposite [45, 51].

Short-chain Carboxylates: Lactate and Succinate

Lactate is present in the colonic lumen at significant concentrations; it can arise from metabolism by different strains of bacteria, particularly *Lactobacilli*, and also can come from diet (e.g., yogurt). Until recently, lactate was considered merely a metabolic end product with relevance to energy production and also a carbon source for gluconeogenesis, but was recently recognized as an important signaling molecule [52]. This recognition stems from the discovery that lactate is an agonist for the cell-surface G-protein-coupled receptor GPR81 [53]. However, there are no published reports on the expression of GPR81 in the intestinal tract. GPR81 is not the only mode of action for lactate; Lee et al. [54] recently identified NDRG3 (N-myc downstream regulated gene 3), an intracellular signaling molecule targeted by lactate that activates downstream signaling pathways involving RAF and ERK. Bacteria-derived lactate and dietary lactate enter colonic epithelial cells via the H⁺-coupled and Na⁺-coupled monocarboxylate transporters expressed on the apical membrane of these cells, but it is not known whether the newly discovered intracellular target NDRG3 is expressed in colonic epithelial cells and contributes to the biological effects of lactate.

Succinate is an additional bacterial metabolite present in the colonic lumen [55]. This metabolite is an inhibitor of the TET family of DNA demethylases and HIF1 α prolyl hydroxylases (PHDs) [56, 57]; as such, succinate has the potential to impact the epigenetic profile of colonic epithelial cells by enhancing DNA methylation and to affect hypoxia signaling by increasing the cellular levels of the transcription factor HIF1 α . However, there is, minimal information on the relevance of succinate to colonic health. Succinate can also affect cellular function via the cell surface G-protein-coupled receptor GPR91 [58]. Similar to NDRG3, it is not known whether GPR91 is expressed in colonic epithelial cells and plays any role in the biology of these cells.

Tryptophan Metabolites

A variety of tryptophan metabolites (e.g., indole, indole-3-aldehyde, indole-3-acetic acid, and indole-3-propionic acid) are generated primarily by bacterial metabolism in the colon and are then absorbed and circulated systemically [59, 60]; thus, plasma levels of these bacterial products are substantially lower in germ-free mice compared to conventional mice [61]. The nuclear receptors AhR (aryl hydrocarbon receptor) and PXR (pregnane/xenobiotic responsive receptor or pregnane X receptor) are molecular targets of these bacteria-derived tryptophan metabolites [59, 60, 62]. The activation of AhR by bacterial-derived tryptophan metabolites elicits anti-inflammatory and tumor-suppressive effects in the colon [63–66]. PXR also regulates cell proliferation, metastasis, and inflammation [67]; as such, bacterial metabolites of tryptophan that activate this receptor may affect the development and severity of colonic inflammation and colon cancer.

Lipids and Lipid Metabolites

Colonic bacteria metabolize bile acids that escape enterohepatic circulation and enter the colon. Hepatocytes synthesize cholic acid and chenodeoxycholic acid, both of which are called “primary” bile acids, but a small portion of these bile acids reaches the colon and is converted into deoxycholic acid and lithocholic acid, respectively. This conversion occurs because of the ability of specific bacteria in the colon to remove the hydroxyl group in cholic acid and chenodeoxycholic acid at position 7 (i.e., 7 α dehydroxylation); these bacteria-modified bile acids are called “secondary” bile acids. Colonic epithelial cells are directly exposed to these bile acids. These bile acids are absorbed into the portal circulation, taken up by hepatocytes, and re-secreted in bile. Normal bile therefore contains not only the primary bile acids but also the bacteria-derived secondary bile acids. Hepatocytes in the liver and absorptive epithelial cells in the ileum are exposed to the bacteria-generated bile acids. Bile acids are not only detergents but also signaling molecules that act through the nuclear receptors pregnane X receptor (PXR) and farnesoid X receptor (FXR) [68]. Bile acids, both primary and secondary, are required for the digestion and absorption of dietary fat and fat-soluble vitamins. In addition, these bile acids affect gene expression in target cells through PXR/FXR-mediated signaling. As such, colonic bacteria influence the biology of intestinal and colonic epithelial cells and hepatocytes. Other lipid metabolites that are generated in the colonic lumen by bacteria include conjugated linoleic and linolenic acids and 10-hydroxy-cis-12-octadecenoate; the molecular targets for these metabolites are the nuclear receptors PPAR α and PPAR γ , and the cell-surface G-protein-coupled receptor GPR40.

It is generally assumed that normal colonic bacteria enhance colonic health and that, as the cohabitation of host and bacteria has evolved over millions of years, the symbiotic relationship does not harm either of the partners in the relationship. Therefore, it came as a surprise when recent studies provided evidence disputing this widely-held notion. Colonic bacteria metabolize dietary lipids into trimethylamine, which is then converted in the liver into a potent cardiovascular toxin, trimethylamine-N-oxide (TMAO) [69**, 70*]. Dietary choline and carnitine are the precursors for the bacterial generation of trimethylamine. Choline is normally found in the diet in the form of phosphatidylcholine (lecithin) and carnitine is a significant constituent of meat. TMAO is associated with atherosclerosis and cardiac events such as myocardial infarction, which provides a molecular link between the diets rich in fat and red meat and increased risk for atherosclerosis [69**, 70*]. The bacterial origin of this cardiovascular toxin became more evident from a recent study in mice that showed that the risk for atherosclerosis could be transmitted through gut microbial transplantation [71]. TMAO enhances platelet hyper-reactivity, activates macrophages, increases the transfer of cholesterol from the liver to peripheral tissues including the vasculature, and decreases the transfer of cholesterol from the periphery to the liver [16, 72, 73]. The molecular target for this cardiovascular toxin, however, remains unknown. The bacterial product TMA, which is the precursor for TMAO, is an agonist for the trace amine-associated receptor TAAR5 [74], but the biological relevance of the activation of this receptor in the colon and liver, the potential target organs for this bacterial metabolite, remains elusive.

Bacterial Cell-wall Components

In addition to the metabolites generated by colonic bacteria, constituents of the bacterial cell wall also serve as signaling molecules in the host. These constituents include lipopolysaccharide, peptidoglycans, and polysaccharide A. The molecular targets for these bacterial cell-wall components are present in colonic epithelial cells as well as in mucosal immune cells. These targets play essential roles in the function of the mucosal immune system. The Toll-like receptor 4 (TLR4), which is activated by lipopolysaccharide, is a cell-surface receptor. Polysaccharide A activates peptidoglycans and TLR2, which in turn activate the intracellular receptors NOD1 and NOD2 (nucleotide-binding domain-containing proteins 1 and 2). These intracellular targets access peptidoglycans or polysaccharide A either via active mechanisms that uptake these ligands or by endocytosis/phagocytosis of the bacteria and subsequent generation of the ligands in the lysosomes following their fusion with endosomes/phagosomes.

Lipopolysaccharides (LPS), also known as endotoxins, constitute the major component of the outer membrane of Gram-negative bacteria. LPS exerts a broad range of biological effects on the intestinal tract, including the colon. It affects intestinal immune response, mucosal cell growth, energy metabolism, nutrient absorption, and mucosal barrier function. For example, it inhibits the absorption of the water-soluble vitamin biotin in the colon by interfering with the translocation of the transporter responsible for absorption to the apical membrane of colonic epithelial cells [75]. It also appears to promote the survival of enteric neurons, thus impacting intestinal motility [76]. The influence of LPS on enteric neurons might, however, depend on diet; high-fat diet induces dysmotility through degeneration of

enteric neurons [77]. It also plays a critical role in intestinal neoplasia; colorectal cancer is associated with overexpression of LPS signaling [78, 79]. Although TLR4 is considered to be the principal cell-surface receptor for LPS, other proteins are also involved in LPS-mediated signaling, both in a TLR4-dependent and TLR4-independent manner. The LPS receptor is a multimeric complex, consisting of at least three proteins: TLR4, CD14, and MD2. CD14 is a membrane-associated protein, anchored to the outer surface of the membrane via the lipid glycosylphosphatidylinositol. It binds LPS and is capable of intracellular signaling independent of TLR4; it also plays a role in presenting LPS to TLR4/MD2 complex to elicit TLR4-dependent intracellular signaling [80, 81]. Of biological importance is the finding that three components of the LPS receptor complex exhibit a differential expression pattern depending on the cell type and the animal species. Normal human colonic epithelial cells express CD14 but not TLR4, whereas normal mouse colonic epithelial cells express both [82**]. In contrast, monocytes, macrophages, and dendritic cells express all three components, in humans as well as in mice [83].

Interestingly, the biological outcome of LPS signaling in colonic epithelial cells varies depending on whether or not TLR4 is co-expressed with CD14. In human colonic epithelial cells, which lack TLR4, the binding of LPS to CD14 causes cell death and suppresses carcinogenesis in a phospholipase C- and sphingomyelinase-dependent manner, whereas the co-expression of TLR4 and CD14 in murine colonic epithelial cells promotes cell survival and carcinogenesis in response to LPS in an NF- κ B-dependent manner [82**]. Human colon cancer tissues as well as most colon cancer cell lines of human origin express both TLR4 and CD14, thus suggesting a role for LPS in promoting proliferation of cancer cells [82**]. As murine colonic epithelial cells normally co-express TLR4 and CD14, overexpression of TLR4 specifically in colonic epithelial cells increases cell proliferation, promotes development of longer colonic crypts, expands Lgr5-positive crypt cells, and potentiates carcinogenesis [84]. There is evidence that LPS-induced signaling via the TLR4/CD14 complex cross-reacts with β -catenin/Wnt pathway to promote colonic neoplasia [84]. In addition, dendritic cells and neutrophils in the lamina propria express acylglycerol hydrolase, an enzyme capable of inactivating LPS via deacylation of its lipid A moiety [85]. The outcome of LPS signaling via TLR4 in colon also depends on whether the exposure of the tissue to LPS is acute or chronic; acute exposure elicits pro-inflammatory effects via promotion of naïve T cell polarization towards Th17-positive cells, whereas chronic exposure elicits an opposite response, promoting immune tolerance via polarization of naïve T cells towards regulatory T cells (Tregs) [86*].

Conclusions

Bacteria in the colon elicit mostly beneficial effects on the host, which include protection against inflammation and carcinogenesis. This phenomenon is principally driven by interactions between specific bacterial metabolites and their respective molecular targets in the host. These interactions inhibit inflammation and tumorigenesis as a result of a broad spectrum of signaling pathways encompassing genetic and epigenetic events. Thus, the assumption that colonic bacteria are silent partners in co-habitation with the host is no longer valid. There is active communication between the bacteria and the host, in both

directions, that enables the symbiotic relationship to work effectively for the benefit of both partners.

Acknowledgments

Funding Support This work was supported by the National Institutes of Health grant CA190710 and by the Welch Endowed Chair in Biochemistry, Grant No. BI-0028, at Texas Tech University Health Sciences Center.

References

Papers of particular interest, published recently, have been highlighted as:

*Of importance

**Of major importance

1. Luckey T. Introduction to intestinal microecology. *Am J Clin Nutr.* 1972; 25:1292–4. [PubMed: 4639749]
- 2**. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacterial cells in the body. *PLoS Biol.* 2016; 14:e1002533. This paper questions one of the most commonly cited value for the ratio of bacterial cells to human cells and provides a revised estimate of this ratio as ~1:1 instead of the previous assumed ~10:1. [PubMed: 27541692]
3. Havenaar R. Intestinal health functions of colonic microbial metabolites: a review. *Benef Microbes.* 2011; 2:103–14. [PubMed: 21840809]
4. Macfarlane GT, Macfarlane S. Bacteria, colonic fermentation, and gastrointestinal health. *J AOAC Int.* 2012; 95:50–60. [PubMed: 22468341]
5. Ramakrishna BS. Role of the gut microbiota in human nutrition and metabolism. *J Gastroenterol Hepatol.* 2013; 28(Suppl 4):9–17. [PubMed: 24251697]
6. Zeng H, Chi H. Metabolic control of regulatory T cell development and function. *Trends Immunol.* 2015; 36:3–12. [PubMed: 25248463]
7. Vipperla K, O’Keefe SJ. The microbiota and its metabolites in colonic mucosal health and cancer risk. *Nutr Clin Pract.* 2012; 27:624–35. [PubMed: 22868282]
8. Shanahan F. The colonic microbiota in health and disease. *Curr Opin Gastroenterol.* 2013; 29:49–54. [PubMed: 23041677]
9. Kovatcheva-Datchary P, Arora T. Nutrition, the gut microbiome and the metabolic syndrome. *Best Pract Res Clin Gastroenterol.* 2013; 27:59–72. [PubMed: 23768553]
10. Fukuda S, Ohno H. Gut microbiome and metabolic diseases. *Semin Immunopathol.* 2014; 36:103–14. [PubMed: 24196453]
- 11*. Schroeder BO, Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. *Nat Med.* 2016; 22:1079–89. This is an outstanding review of the literature summarizing the signals from the gut bacteria that travel to distant organs and influence their function in health and disease. [PubMed: 27711063]
12. Bhutia YD, Ganapathy V. Short, but smart: SCFAs train T cells in the gut to fight autoimmunity in the brain. *Immunity.* 2015; 43:629–31. [PubMed: 26488813]
- 13**. Haghikia A, Jorg S, Duscha A, et al. Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine. *Immunity.* 2015; 43:817–29. This study demonstrates that dietary fatty acids, by modulating gut microbiota and their metabolism, regulate immune cells in the gut, which then travel to the periphery to impact systemic immunity. [PubMed: 26488817]
14. Kuhn KA, Stappenbeck TS. Peripheral education of the immune system by the colonic microbiota. *Semin Immunol.* 2013; 25:364–9. [PubMed: 24169518]
15. Selkig J, Wong P, Zhang X, Pettersson S. Metabolic tinkering by the gut microbiome: Implications for brain development and function. *Gut Microbes.* 2014; 5:369–80. [PubMed: 24685620]
16. Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. *J Clin Invest.* 2014; 124:4204–11. [PubMed: 25271725]

17. Vamanu E, Pelinescu D, Sarbu I. Comparative fingerprinting of the human microbiota in diabetes and cardiovascular disease. *J Med Food*. 2016; doi: 10.1089/jmf.2016.0085
18. Blandino G, Inturri R, Lazzara F, et al. Impact of gut microbiota on diabetes mellitus. *Diabetes Metab*. 2016; doi: 10.1016/j.diabet.2016.04.004
19. Kraneveld AD, Szklany K, de Theije CG, Garssen J. Gut-to-brain axis in autism spectrum disorders: central role for the microbiome. *Int Rev Neurobiol*. 2016; 131:263–87. [PubMed: 27793223]
20. Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short-chain fatty acids. *Nutrients*. 2011; 3:858–76. [PubMed: 22254083]
21. Felice C, Lewis A, Armuzzi A, Lindsay JO, Silver A. Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases. *Aliment Pharmacol Ther*. 2015; 41:26–38. [PubMed: 25367825]
22. Thangaraju M, Gopal E, Martin PM, et al. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases. *Cancer Res*. 2006; 66:11560–4. [PubMed: 17178845]
23. Singh N, Thangaraju M, Prasad PD, et al. Blockade of dendritic cell development by bacterial fermentation products butyrate and propionate through a transporter (Slc5a8)-dependent inhibition of histone deacetylases. *J Biol Chem*. 2010; 285:27601–8. [PubMed: 20601425]
24. Thangaraju M, Cresci GA, Liu K, et al. GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. *Cancer Res*. 2009; 69:2826–32. [PubMed: 19276343]
25. Tazoe H, Otomo Y, Kaji I, et al. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. *J Physiol Pharmacol*. 2008; 59(Suppl 2):252–62.
26. Ganapathy V, Thangaraju M, Prasad PD, Martin PM, Singh N. Transporters and receptors for short-chain fatty acids as the molecular link between colonic bacteria and the host. *Curr Opin Pharmacol*. 2013; 13:869–74. [PubMed: 23978504]
27. Tan J, McKenzie C, Potamitis M, Thorburn AN, Mackay CR, Macia L. The role of short-chain fatty acids in health and disease. *Adv Immunol*. 2014; 121:91–119. [PubMed: 24388214]
28. Ganapathy V, Thangaraju M, Gopal E, et al. Sodium-coupled monocarboxylate transporters in normal tissues and in cancer. *AAPS J*. 2008; 10:193–9. [PubMed: 18446519]
29. Marchiq I, Pouyssegur J. Hypoxia, cancer metabolism and the therapeutic benefit of targeting lactate/H⁺ symporters. *J Mol Med*. 2016; 94:155–71. [PubMed: 26099350]
30. Ganapathy V, Thangaraju M, Prasad PD. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. *Pharmacol Ther*. 2009; 121:29–40. [PubMed: 18992769]
31. Bhutia YD, Babu E, Ramachandran S, Yang S, Thangaraju M, Ganapathy V. SLC transporters as a novel class of tumour suppressors: identity, function and molecular mechanisms. *Biochem J*. 2016; 473:1113–24. [PubMed: 27118869]
32. Li H, Myeroff L, Smiraglia D, et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. *Proc Natl Acad Sci USA*. 2003; 100:8412–7. [PubMed: 12829793]
33. Miyauchi S, Gopal E, Fei YJ, Ganapathy V. Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na⁺-coupled transporter for short-chain fatty acids. *J Biol Chem*. 2004; 279:13293–6. [PubMed: 14966140]
34. Frank H, Groger N, Diener M, Becker C, Braun T, Boettger T. Lactaturia and loss of sodium-dependent lactate uptake in the colon of SLC5A8-deficient mice. *J Biol Chem*. 2008; 283:24729–37. [PubMed: 18562324]
- 35*. Gurav A, Sivaprakasam S, Bhutia YD, Boettger T, Singh N, Ganapathy V. Slc5a8, a Na⁺-coupled high-affinity transporter for short-chain fatty acids, is a conditional tumour suppressor in colon that protects against colitis and colon cancer under low-fibre dietary conditions. *Biochem J*. 2015; 469:267–78. This study demonstrated a link between the tumor-suppressive function of the short-chain fatty acid transporter SLC5A8 and the dietary fiber content and provided a reasonable explanation as to why Slc5a8-null mice do not show increased risk for colitis and colon cancer under normal dietary conditions. [PubMed: 25984582]

36. Cresci GA, Thangaraju M, Mellinger JD, Liu K, Ganapathy V. Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8. *J Gastrointest Sug.* 2010; 14:449–61.
- 37*. Singh N, Gurav A, Sivaprakasam S, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. *Immunity.* 2014; 40:128–39. This study demonstrated unequivocally the anti-inflammatory and tumor-suppressive function of the butyrate receptor GPR109A in vivo using Gpr109a-null mice. [PubMed: 24412617]
38. Taggart AK, Kero J, Gan X, et al. (D)- β -hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. *J Biol Chem.* 2005; 280:26649–52. [PubMed: 15929991]
- 39*. Tan J, KcKenzie C, Vuillermin PJ, et al. Dietary fiber and bacterial SCFA enhance oral tolerance and protect against food allergy through diverse cellular pathways. *Cell Rep.* 2016; 15:2809–24. Here the authors showed that a high fiber content in the diet improved oral tolerance and offered protection against food allergy, and that deletion of Gpr43 or Gpr109a in mice exacerbated food allergy. [PubMed: 27332875]
40. Ang Z, Ding JL. GPR41 and GPR43 in obesity and inflammation – protective or causative? *Front Immunol.* 2016; 7:28. [PubMed: 26870043]
41. Tazoe H, Otomo Y, Karaki S, et al. Expression of short-chain fatty acid receptor GPR41 in the human colon. *Biomed Res.* 2009; 30:149–56. [PubMed: 19574715]
42. Karaki S, Mitsui R, Hayashi H, et al. Short-chain fatty acid receptor, Gpr43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. *Cell Tissue Res.* 2006; 324:353–60. [PubMed: 16453106]
43. Karaki S, Tazoe H, Hayashi H, et al. Expression of the short-chain fatty acid receptor, GPR43, in the human colon. *J Mol Histol.* 2008; 39:135–42. [PubMed: 17899402]
44. Trompette A, Gollwitzer ES, Yadava K, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. *Nat Med.* 2014; 20:159–66. [PubMed: 24390308]
45. Kime MH, Kang SG, Park JH, Yanagisawa M, Kim CH. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. *Gastroenterology.* 2013; 145:396–406. [PubMed: 23665276]
46. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature.* 2009; 461:1282–6. [PubMed: 19865172]
47. Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science.* 2013; 341:569–73. [PubMed: 23828891]
48. Masui R, Sasaki M, Funaki Y, et al. G protein-coupled receptor 43 moderates gut inflammation through cytokine regulation from mononuclear cells. *Inflamm Bowel Dis.* 2013; 19:2848–56. [PubMed: 24141712]
49. Macia L, Tan J, Vieira AT, et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. *Nat Commun.* 2015; 6:6734. [PubMed: 25828455]
50. Sivaprakasam S, Gurav V, Paschall AV, et al. An essential role of Ffar2 (Gpr43) in dietary fibre-mediated promotion of healthy composition of gut microbiota and suppression of intestinal carcinogenesis. *Oncogenesis.* 2016; 5:e238. [PubMed: 27348268]
51. Sina C, Gavrilova O, Forster M, et al. G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. *J Immunol.* 2009; 183:7514–22. [PubMed: 19917676]
52. Choi SY, Collins CC, Gout PW, Wang Y. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? *J Pathol.* 2013; 230:350–5. [PubMed: 23729358]
53. Liu C, Wu J, Zhu J, et al. Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor. *J Biol Chem.* 2009; 284:2811–22. [PubMed: 19047060]
54. Lee DC, Sohn HA, Park ZY, et al. A lactate-induced response to hypoxia. *Cell.* 2015; 161:595–609. [PubMed: 25892225]
55. Jakobsdottir G, Xu J, Molin G, Ahme S, Nyman M. High-fat diet reduces the formation of butyrate, but increases succinate, inflammation, liver fat and cholesterol in rats, while dietary fibre counteracts these effects. *PLoS One.* 2013; 8:e80476. [PubMed: 24236183]

56. Yang M, Pollard PJ. Succinate: a new epigenetic hacker. *Cancer Cell*. 2013; 23:709–11. [PubMed: 23763995]
57. Boulahbel H, Duran RV, Gottlieb E. Prolyl hydroxylases as regulators of cell metabolism. *Biochem Soc Trans*. 2009; 37:291–4. [PubMed: 19143649]
58. He W, Miao FJ, Lin DC, et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. *Nature*. 2004; 429:188–93. [PubMed: 15141213]
59. Hubbard TD, Murray IA, Perdew GH. Indole and tryptophan metabolism: Endogenous and dietary routes to Ah receptor activation. *Drug Metab Dispos*. 2015; 43:1522–35. [PubMed: 26041783]
60. Jin UH, Lee SO, Sridharan G, et al. Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and antagonist activities. *Mol Pharmacol*. 2014; 85:777–88. [PubMed: 24563545]
61. Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. *Proc Natl Acad Sci USA*. 2009; 106:3698–703. [PubMed: 19234110]
62. Venkatesh M, Mukherjee S, Wang H, et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. *Immunity*. 2014; 41:296–310. [PubMed: 25065623]
63. Stockinger B, Di Meglio P, Gialitakis M, Duarte JH. The aryl hydrocarbon receptor: multitasking in the immune system. *Annu Rev Immunol*. 2014; 32:403–32. [PubMed: 24655296]
64. Xie G, Raufman JP. Role of the aryl hydrocarbon receptor in colon neoplasia. *Cancers*. 2015; 7:1436–46. [PubMed: 26264025]
65. Goettel JA, Gandhi R, Kenison JE, et al. AHR activation is protective against colitis driven by T cells in humanized mice. *Cell Rep*. 2016; 17:1318–29. [PubMed: 27783946]
66. Diaz-Diaz CJ, Ronnekleiv-Kelly SM, Nukaya M, Geiger PG, et al. The aryl hydrocarbon receptor is a repressor of inflammation-associated colorectal tumorigenesis in mouse. *Ann Surg*. 2016; 264:429–36. [PubMed: 27433903]
67. Pondugula SR, Pavek P, Mani S. Pregnane X receptor and cancer: Context-specificity is key. *Nucl Receptor Res*. 2016; 3:101198. pii. [PubMed: 27617265]
68. Jonker JW, Liddle C, Downes M. FXR and PXR: potential therapeutic targets in cholestasis. *J Steroid Biochem Mol Biol*. 2012; 130:147–58. [PubMed: 21801835]
- 69*. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. *Nat Med*. 2013; 19:576–85. This was the first report on the generation of trimethylamine (TMA) in the colon by bacterial metabolism of diet-derived carnitine and the subsequent hepatic conversion of TMA into the cardiovascular toxin TMA oxide, thus providing a mechanistic link between high dietary intake of carnitine-rich red meat and risk for cardiovascular disease. [PubMed: 23563705]
- 70*. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N Engl J Med*. 2013; 368:1575–84. This study provides evidence for the association between increased plasma levels of TMAO and risk for cardiovascular disease and also for dietary lipid phosphatidylcholine as the source for colonic bacterial metabolism to generate TMA, the precursor for TMAO. [PubMed: 23614584]
71. Gregory JC, Buffa JA, Org E, et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. *J Biol Chem*. 2015; 290:5647–60. [PubMed: 25550161]
72. Brown JM, Hazen SL. The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. *Annu Rev Med*. 2015; 66:343–59. [PubMed: 25587655]
73. Wilson A, McLean C, Kim RB. Trimethylamine-N-oxide: a link between the gut microbiome, bile acid metabolism, and atherosclerosis. *Curr Opin Lipidol*. 2016; 27:148–54. [PubMed: 26959704]
74. Wallrabenstein I, Kuklan J, Weber L, et al. Human trace amine-associated receptor TAAR5 can be activated by trimethylamine. *PLoS One*. 2013; 8:e54950. [PubMed: 23393561]
75. Lakhan R, Said M. Lipopolysaccharide inhibits colonic biotin uptake via interference with membrane expression of its transporter: a role for casein kinase 2-mediated pathway. *Am J Physiol Cell Physiol*. 2017; doi: 10.1152/ajpcell.00300.2016

76. Anitha M, Vijay-Kumar M, Sitaraman SV, Gewirtz AT, Srinivasan S. Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling. *Gastroenterology*. 2012; 143:1006–16. [PubMed: 22732731]
77. Reichardt F, Chassaing B, Nezami BG, et al. Western diet induces colonic nitroergic myenteric neuropathy and dysmotility in mice via saturated fatty acid- and LPS-induced TLR4 signaling. *J Physiol*. 2016; doi: 10.1113/JP273269
78. Cario E. Microbiota and innate immunity in intestinal inflammation and neoplasia. *Curr Opin Gastroenterol*. 2013; 29:85–91. [PubMed: 23207600]
79. Kamba A, Lee IA, Mizoguchi E. Potential association between TLR4 and chitinase 3-like 1 (CHI3L1/YKL40) signaling on colonic epithelial cells in inflammatory bowel disease and colitis-associated cancer. *Curr Mol Med*. 2013; 13:1110–21. [PubMed: 23170831]
80. Jiang Q, Akashi S, Miike K, Petty HR. Lipopolysaccharide induces physical proximity between CD14 and Toll-like receptor 4 (TLR4) prior to nuclear translocation of NF- κ B. *J Immunol*. 2000; 165:3541–4. [PubMed: 11034352]
81. de Silva Correia J, Soldau K, Christen U, Tobias PS, Ulevitch RJ. Lipopolysaccharide is close proximity to each of the proteins in its membrane receptor complex; transfer from CD14 to TLR4 and MD2. *J Biol Chem*. 2001; 276:21129–35. [PubMed: 11274165]
82. Kuo WT, Lee TC, Yang HY, et al. LPS receptor subunits have antagonistic roles in epithelial apoptosis and colonic carcinogenesis. *Cell Death Diff*. 2015; 22:1590–604. This study provided the molecular rationale for the antagonistic actions of LPS in colonic epithelium via the presence or absence of the co-expression of CD14 with TLR4.
83. Ishida A, Akita K, Mori Y, et al. Negative regulation of Toll-like receptor-4 signaling through the binding of glycosylphosphatidylinositol-anchored glycoprotein, CD14, with the sialic acid-binding lectin, CD33. *J Biol Chem*. 2014; 289:25341–50. [PubMed: 25059667]
84. Santaolalla R, Sussman DA, Ruiz JR, et al. TLR4 activates the β -catenin pathway to cause intestinal neoplasia. *PLoS One*. 2013; 8:e63298. [PubMed: 23691015]
85. Munford RS, Hall CL. Detoxification of bacterial lipopolysaccharide (endotoxins) by a human neutrophil enzyme. *Science*. 1986; 234:203–5. [PubMed: 3529396]
- 86*. Janelins BM, Lu M, Datta SK. Altered inactivation of commensal LPS due to acyloxyacyl hydrolase deficiency in colonic dendritic cells impairs mucosal Th17 immunity. *Proc Natl Acad Sci USA*. 2014; 111:373–8. This study describes the role of chronic exposure of the colon to LPS in the polarization of naïve T cells towards pro-inflammatory Th17-positive T cells or immunosuppressive regulatory T cells (Tregs). [PubMed: 24344308]

Table 1

Bacterial metabolites and their molecular targets in the host

Metabolites	Targets
Short-chain carboxylates	
Acetate, Propionate, Butyrate	GPR41, GPR43, HDACs
Butyrate	GPR109A, HDACs
Lactate	GPR81, NDRG3
Succinate	GPR91, TETs, PHD2
Tryptophan metabolites	
Indole, Indole-3-aldehyde	AhR
Indole-3-acetic acid	AhR
Indole-3-propionic acid	PXR
Lipids and lipid metabolites	
Trimethylamine	TAAR5
Deoxycholic acid, Lithocholic acid	FXR, PXR
Conjugated Linoleic and Linolenic acids	PPAR α , PPAR γ
10-Hydroxy-cis-12-octadecenoate	GPR40
Bacterial cell-wall components	
Lipopolysaccharide	TLR4
Peptidoglycans	NOD1, NOD2
Polysaccharide A	TLR2